Imidazole-modified porphyrin as a pH-responsive sensitizer for cancer photodynamic therapy

Chem Commun (Camb). 2011 Oct 7;47(37):10311-3. doi: 10.1039/c1cc13328d. Epub 2011 Aug 19.

Abstract

5,10,15,20-Tetrakis(N-(2-(1H-imidazol-4-yl)ethyl)benzamide)porphyrin produced twice as many singlet oxygen ((1)O(2)) molecules at pH 5.0 (quantum yield 0.53 ± 0.01) than at pH 7.4, whereas the (1)O(2) quenching rate was reduced by a factor of 2.5 for a pH change from 7.4 to 5.0.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / pathology
  • Amides / chemistry
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Carboxylic Acids / chemistry
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Cell Survival / radiation effects
  • Female
  • Humans
  • Hydrogen-Ion Concentration
  • Imidazoles / chemistry*
  • Photochemotherapy / methods*
  • Photosensitizing Agents / chemical synthesis
  • Photosensitizing Agents / chemistry
  • Photosensitizing Agents / pharmacology
  • Porphyrins / chemical synthesis
  • Porphyrins / chemistry*
  • Porphyrins / pharmacology*
  • Singlet Oxygen / chemistry

Substances

  • 5,10,15,20-tetrakis(N-(2-(1H-imidazol-4-yl)ethyl)benzamide)porphyrin
  • Amides
  • Carboxylic Acids
  • Imidazoles
  • Photosensitizing Agents
  • Porphyrins
  • Singlet Oxygen